Literature DB >> 21470510

ADT and the metabolic syndrome: no good deed goes unpunished.

Jehonathan H Pinthus1.   

Abstract

Entities:  

Year:  2011        PMID： 21470510      PMCID： PMC3036753          DOI： 10.5489/cuaj.11017

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  8 in total

Review 1.  Cardiovascular effects of androgen depletion and replacement therapy.

Authors:  Jehonathan H Pinthus; John Trachtenberg; Laurence Klotz
Journal:  Urology       Date:  2006-06       Impact factor: 2.649

2.  Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Authors:  Milena Braga-Basaria; Adrian S Dobs; Denis C Muller; Michael A Carducci; Majnu John; Josephine Egan; Shehzad Basaria
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

Review 3.  Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

Authors:  Jason E Faris; Matthew R Smith
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-06       Impact factor: 3.243

4.  Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.

Authors:  Matthew R Smith; Laurence Klotz; Bo-Eric Persson; Tine Kold Olesen; Arthur A M Wilde
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

5.  Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer.

Authors:  Hassanabbas Z Mohamedali; Henriette Breunis; Narhari Timilshina; Shabbir M H Alibhai
Journal:  Can Urol Assoc J       Date:  2011-02       Impact factor: 1.862

Review 6.  The role of testosterone in the metabolic syndrome: a review.

Authors:  Farid Saad; Louis Gooren
Journal:  J Steroid Biochem Mol Biol       Date:  2009-03       Impact factor: 4.292

7.  Effective testosterone suppression for prostate cancer: is there a best castration therapy?

Authors:  Leonard G Gomella
Journal:  Rev Urol       Date:  2009

8.  Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

Authors:  Juan Morote; Anna Orsola; Jacques Planas; Enrique Trilla; Carles X Raventós; Lluís Cecchini; Roberto Catalán
Journal:  J Urol       Date:  2007-08-14       Impact factor: 7.450
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.